Divestment of sepofarsen and ultevursen completed – Théa to …
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
IN THE NEWS
12/04/2023
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy…
ATSN-101 continues to demonstrate clinically meaningful impr…
11/14/2023
Atsena Therapeutics Receives FDA Regenerative Medicine Advanced The…
RMAT designation recognizes the potential of ATSN-101 to add…
11/03/2023
New Preliminary Clinical Data on Potential of Opus AAV-based Gene T…
Data to be presented as part of gene augmentation therapy pr…
10/16/2023
The Retinal Degeneration Fund Announces an Investment in NVasc
NVasc is developing a therapeutic angiogenesis strategy for …
09/26/2023
SparingVision Selects Second Target in Strategic Collaboration with…
Milestone broadens partnership to develop novel ocular thera…
09/07/2023
Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of G…
OPGx-LCA5 is designed to address vision loss due to Leber co…
08/30/2023
SparingVision Reports Positive Initial Safety Data from the first c…
- Lead gene therapy asset, SPVN06, reported to be well-toler…
08/24/2023
The Retinal Degeneration Fund announces an investment in Amber Bio
Amber Bio is developing a first-of-its-kind RNA writing plat…
08/03/2023
Amber Bio Raises $26 Million Seed Financing Co-Led by Playground Gl…
Amber Bio’s proprietary platform leverages multi-kilobase RN…
08/01/2023
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Thé…
Agreement provides ProQR with initial payment of €12.5M and …
07/11/2023
Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluatin…
New clinical site added and early safety signals observed in…